Drugs / NB02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07114367 | Dec 2025 → Dec 2026 expected | non-Hodgkin lymphoma | NOBO Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07114367 ↗ |
| Known as | Poseltinib | “NB02 (Poseltinib)” NCT07114367 ↗ |